A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA)

Trial Profile

A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs TDM 812 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Mar 2017 Planned End Date changed from 30 Sep 2017 to 31 Jan 2018.
    • 20 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top